Recently, Shenzhen Core Medical Technology Co., Ltd. announced that its flagship product, the Corheart® 6 implantable left ventricular assist system (implantable artificial heart), has completed its 1,000th implantation. This makes it the world's second third-generation fully magnetically levitated artificial heart (after Abbott's HeartMate 3, launched in 2015) and the first such domestically produced device to surpass the 1,000-case milestone.

As the latest domestic product to enter the market but the first to reach 1,000 implantations, Corheart® 6 secured over 50% market share in 2025, firmly establishing itself as the leader in the domestic artificial heart field. As a high-risk innovative medical device enterprise in China, Core Medical has successfully translated its advanced R&D and technological strength into tangible social and economic benefits, achieving full realization from technological breakthrough to commercial application.

Core Medical pioneered the "time-sharing, regional dynamic axial fully magnetically levitated control technology" in the artificial heart field. Corheart® 6 features a "simpler structure, lighter weight, smaller size, and lower power consumption." Clinically, the product offers "smaller surgical incisions, faster patient recovery, applicability to a broader patient population, and reduced risk of thrombosis caused by heat from the blood pump," demonstrating that "China Smart Manufacturing" has reached internationally leading levels in the artificial heart field.

Throughout its development journey, Core Medical has consistently embodied "speed" and "stability" through innovation-driven and superior performance. On the international front, leveraging its proprietary magnetic levitation control technology and outstanding product capabilities, Core Medical has achieved continuous breakthroughs overseas. In 2024, it completed its first overseas implantation in Austria, marking the first time a Chinese enterprise has performed a clinical application of a high-risk active implantable device overseas.

Currently, the commercially available and widely used artificial heart products globally mainly include Abbott's HeartMate 3 (implantable) and Johnson & Johnson's Impella series (interventional). If the CorVad® series products receive formal marketing approval, Core Medical will become the world's only enterprise with both commercialized implantable and interventional artificial heart products. The synergistic effect of the two product lines in clinical application will further strengthen Core Medical's comprehensive competitiveness and global leadership in the heart failure treatment field.